Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umeclidinium bromide add-on to Fluticasone/Salmeterol in COPD
NCT01772147Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2013
- Primary completion
- Aug 2013
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of umeclidinium in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by GSK. Primary endpoint: Change From Baseline in the Trough Forced Expiratory Volume in One Second at Day 85. Started Jan 2013; status: completed.
02
Drugs
umeclidinium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01772147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01772147.